STOCK TITAN

Haleon (NYSE: HLN) completes 2.75M-share buyback and updates voting rights

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Haleon plc reported recent purchases of its own shares under a previously announced buyback programme. The company bought 2,749,486 ordinary shares of £0.01 each for cancellation on 12 and 13 March 2026 across the London Stock Exchange, CBOE UK venues and Aquis.

After these transactions settle, Haleon’s registered share capital will be 8,949,604,162 ordinary shares, including 43,651,673 held in treasury. This leaves 8,905,952,489 ordinary shares with voting rights, a figure shareholders can use for regulatory disclosure thresholds.

Positive

  • None.

Negative

  • None.
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March 2026
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
16 March 2026 - “Transactions in Own Shares”
 
 
 
 
99.1
 
 
Haleon plc: Aggregated information - transactions in own shares
 
16 March 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,749,486 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.
 
 
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Aquis
Date of purchase:
12 March 2026
Number of Shares purchased:
581,608
-
425,404
242,474
Highest price paid per Share (p):
376.6000
-
376.2000
376.2000
Lowest price paid per Share (p):
369.3000
-
369.3000
369.3000
Volume weighted average price paid per Share (p):
373.2269
-
373.3763
373.6357
Date of purchase:
13 March 2026
Number of Shares purchased:
701,879
325,243
472,878
-
Highest price paid per Share (p):
377.8000
377.8000
377.8000
-
Lowest price paid per Share (p):
370.8000
370.8000
370.8000
-
Volume weighted average price paid per Share (p):
375.3797
375.4187
375.3606
-
 
Following the settlement of the above, the Company's registered share capital is 8,949,604,162 ordinary shares of £0.01 each, of which 43,651,673 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,905,952,489 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/6653W_1-2026-3-13.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 
Enquiries
 
 
Investors
Media
 
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as AdvilCentrumOtrivinPanadolparodontaxPolidentSensodyneTheraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
 
For more information, please visit www.haleon.com
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: March 16, 2026
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary

FAQ

What did Haleon plc (HLN) announce in this Form 6-K?

Haleon plc disclosed the purchase of its own shares under a share buyback programme. It bought 2,749,486 ordinary shares for cancellation, executed over several trading venues, and updated investors on the new total share capital and voting rights following these transactions.

How many Haleon (HLN) shares were repurchased and cancelled?

Haleon repurchased 2,749,486 ordinary shares of £0.01 each for cancellation as part of its buyback programme. These purchases took place on 12 and 13 March 2026 across the London Stock Exchange, CBOE UK markets and Aquis, reducing the free-float share count.

What is Haleon plc’s total share capital after these buybacks?

After settlement, Haleon’s registered share capital is 8,949,604,162 shares of £0.01 each. Of these, 43,651,673 are held as treasury shares. The remaining shares form the basis for ownership and regulatory disclosure calculations under UK transparency rules.

How many Haleon (HLN) shares currently carry voting rights?

Haleon reports 8,905,952,489 ordinary shares with voting rights after the latest buybacks and treasury holdings. Shareholders can use this voting share figure to assess their percentage ownership and whether they must notify changes under FCA Disclosure Guidance and Transparency Rules.

Where can investors find detailed Haleon share buyback trade data?

Investors can access a full breakdown of the individual trades via a linked PDF on the London Stock Exchange website and through Haleon’s investor relations site. The company provides venue-level and trade-level information to support transparency around its share buyback activity.

Does Haleon’s announcement involve an offer of new securities?

No, the announcement does not constitute an offer of securities in any jurisdiction. It strictly reports repurchases of existing Haleon shares for cancellation under the company’s buyback programme, rather than any new issuance or solicitation to buy securities.
Haleon

NYSE:HLN

View HLN Stock Overview

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

44.85B
4.45B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge